The Evolution of Biomarkers in Thyroid Cancer—From Mass Screening to a Personalized Biosignature

Cancers

Raymon H. Grogan¹  Elliot J. Mitmaker¹ 

关键词: thyroid cancer;    biomarker;    biological marker;    molecular marker;    tumor marker;    molecular pathways;    epigenetics;    serum based biomarkers;    genomics;    proteomics;   

DOI  :  10.3390/cancers2020885

来源: mdpi

【 摘 要 】

Thyroid cancer is the most common malignancy of the endocrine system. The diagnosis of thyroid nodules, made by neck examination and ultrasonography, is a common event occurring in over 50% of the patient population over the age of 50. Yet, only 5% of these patients will be diagnosed with cancer. Fine needle aspiration biopsy is the gold standard for diagnosing thyroid nodules. However, 10–15% of these biopsies are inconclusive, ultimately requiring a diagnostic thyroid lobectomy. Consequently, research in thyroid biomarkers has become an area of active interest. In the 40 years since calcitonin was first described as the biomarker for medullary thyroid cancer, new biomarkers in thyroid cancer have been discovered. Advances in genomic and proteomic technologies have defined many of these novel thyroid biomarkers. The purpose of this article is to provide a comprehensive literature review of how these biomarkers have evolved from simple screening tests into a complex array of multiple markers to help predict the malignant potential and genetic signature of thyroid neoplasms.

【 授权许可】

CC BY   
© 2010 by the authors; licensee MDPI, Basel, Switzerland.